{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Kazia Therapeutics Limited"},"Symbol":{"label":"Symbol","value":"KZIA"},"Address":{"label":"Address","value":"300 BARANGAROO AVENUE,LEVEL 24, SYDNEY, 2000, Australia"},"Phone":{"label":"Phone","value":"+61 294724101"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Australia and South Pacific"},"CompanyDescription":{"label":"Company Description","value":"Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others."},"CompanyUrl":{"label":"Company Url","value":"https://www.kaziatherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"John E. Friend","title":"Chief Executive Officer & Managing Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}